Correction. In the article "Molecular determinants of immunogenicity: The immunon model of immune response" by H.
Correction. In the article "Diphenylhydantoin (Dilantin) gingival hyperplasia: Drug-induced abnormality of connective tissue" by T. M. Hassell, R. C. Page, A. S. Narayanan, and C. G. Cooper, which appeared in the August 1976 issue of Proc. Natl. Acad. Sci. USA 73, 2909-2912, the authors have requested changes in the protein data in Table 2 The experiments were performed with cells that had been maintained in the absence of dph for at least three to six passages. Thus, the phenotype was stable through several generations. The enhanced synthetic capacity could not be accounted for by an increased number of cells in the responder cultures, since the DNA and protein per plate were not significantly different among cultures of the various types (Table 2 ). There were no significant differences among the three experimental groups with regard to prolyl hydroxylase or lysyl oxidase ac- tivities (see Table 3 ), whether or not dph was added to the culture medium. DISCUSSION Gingival overgrowth, which may be of sufficient magnitude to completely obscure the teeth, occurs in approximately onehalf of all patients taking sodium 5,5-diphenylhydantoinate (Dilantin, dph), a drug widely used in the treatment of epilepsy (see refs. [7] [8] [9] [10] [11] [12] [13] [14] [15] . The lesion exhibits site and age specificity. The gingival tissues around the anterior teeth are more severely and more frequently affected than those around the posterior teeth (16) , and most of the overgrowth begins in the tissues adjacent to the proximal and labial tooth surfaces (17) . The Pathologic changes occur only rarely in connective tissues other than the gingiva, although Houck et al. (19) have described a dermal reaction to dph administration in rats, and wounds in animals given dph heal with the formation of strong fibrous scars (20, 21) . Thickening of the bone of the calvaria in children taking the drug for long time periods has been described (22) . Most animals are not susceptible to the disease, but it has been induced in cats (23) , ferrets (24) , and very recently in monkeys (25) . Thus, the lesion has a very complex etiology and pathogenesis, requiring not only regular intake of the drug for fairly long time periods (6 months or more), but also a specific site in a susceptible host of young age, and persistent local irritation or antigenic stimulation of the tissue. The tissue overgrowth, which is generally referred to incorrectly as a "hyperplasia, " is made up almost completely of dense collagenous tissue with scattered chronic inflammatory cells. The resident connective tissue cells do not appear to be abnormal in morphology or number (26) , and, except in quantity and architecture, the collagenous material seems normal (27, 26) . In these respects the dph-induced lesion resembles other forms of fibrosis. - Dilantin gingival overgrowth is not a problem of major clinical significance; however, it may be a satisfactory model permitting analysis of some aspects of very common connective tissue abnormalities such as fibrosis, about which almost nothing is known, but which are important components of most chronic lesions.
Our observations show that fibroblasts obtained from the overgrown tissue sites of four out of five individuals tested and maintained in culture in the absence of dph for several passages synthesize about twice as much protein as normal control cells or cells from nonresponder individuals. In addition, a much larger portion of the synthetic activity of the abnormal cells is directed toward the production of collagen. Similar behavior by fibroblasts in the overgrown tissue in vivo would likely result in a lesion of the type observed clinically in Dilantin hyperplasia. Whether or not cells obtained from other fibrotic lesions such as hypertrophic burn scars, keloid, arthritic joints, lupus, and scleroderma would behave in a similar manner remains unknown, although the work of LeRoy (28) indicates that at least in scleroderma this may be the case.
The mechanism by which dph induces its effects on fibroblasts remains obscure, although several possibilities merit consideration. The drug could modulate gene action or cell synthetic activity through direct interaction with cytoplasmic structures or other factors. However, this hypothesis appears to be incompatible with the persistence of the defect in cells carried through several passages in vitro without drug. Diphenylhydantoin may be a mutagen. Synthetic activity of fibroblasts and many other cells appears to be under the influence of intracellular levels of cyclic nucleotides and these, in turn, may be controlled by levels of cellular hormones such as the prostaglandins. The drug could induce a mutation resulting in the production of a defective protein binding site for effector molecules such as the prostaglandins, or a defective enzyme participating in cyclic nucleotide metabolism. An additional possibility would be the induction of a mutation at a specific genetic regulatory site normally controlling the magnitude of protein synthesis and dictating the proportion of total synthetic activity to be directed toward collagen production.
Although the mutagen hypothesis is supported by the observation that dph may induce chromosomal alterations under some conditions (29) , it seems unlikely for several reasons.
Mutagens generally are not site specific; they induce a range of mutations. Single genetic loci controlling total protein synthesis as well as collagen synthesis are not known to exist. Furthermore, the host selectivity, age relationship, microbial plaque dependency, and spontaneous regression of the lesion that follows withdrawal of the drug are inconsistent with dph-induced genetic alterations.
The hypothesis which appears most compatible with our observations is that of selection of an unusual cell population by the (32) . These variations in collagen type, amount, and turnover time may be functions of the particular cell populations maldng up the tissue at a given point in time, rather than modulation of the activities of a single cell type.
A small portion of the fibroblasts normally present in gingiva, in healing wounds, and possibly in other tissues, may possess the properties we have observed in cultures of cells derived from responder individuals. A unique combination of conditions existing in the gingival tissues of responder individuals may lead to amplification of the population size of cells with these properties through selective growth pressures. Indeed, dph is reported to be mildly cytotoxic (33, 34) . Unique conditions, in addition to the appropriate concentration of the drug, may include a young, genetically susceptible individual who is experiencing a chronic inflammatory response in the gingival tissues initiated by bacterial substances on the teeth. A mechanism involving cell selection could underlie differentiation and aging of normal connective tissues as well as pathologic alterations such as fibrosis.
